BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37960766)

  • 21. Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma.
    Wang C; Chen Q; Luo H; Chen R
    World J Surg Oncol; 2023 Mar; 21(1):76. PubMed ID: 36871027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of chromobox protein (CBX) expression in diffuse LBCL.
    Hu CY; Li X; Zeng T; Ye DM; Li YK; Yan HX
    Gene; 2022 Mar; 813():146092. PubMed ID: 34896523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long non-coding RNA TRIM52-AS1 sponges microRNA-577 to facilitate diffuse large B cell lymphoma progression via increasing TRIM52 expression.
    Zhao F; Li S; Liu J; Wang J; Yang B
    Hum Cell; 2022 Jul; 35(4):1234-1247. PubMed ID: 35676608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.
    Zhang YA; Yang X; Yao J; Ren Y; Liu P
    Dis Markers; 2022; 2022():3276925. PubMed ID: 35774848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression and Clinical Significance of Exosome Component 4 in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma].
    Hong JQ; Huang QH; Huang ZY; Fan LP; Lin QY; Huang HB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1684-1689. PubMed ID: 38071046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.
    Chen W; Wang H; Chen H; Liu S; Lu H; Kong D; Huang X; Kong Q; Lu Z
    Eur J Haematol; 2014; 92(5):407-12. PubMed ID: 24400911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
    Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
    Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma.
    Nan YY; Zhang WJ; Huang DH; Li QY; Shi Y; Yang T; Liang XP; Xiao CY; Guo BL; Xiang Y
    World J Clin Cases; 2021 Jun; 9(18):4585-4598. PubMed ID: 34222425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
    Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
    Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-germinal center B-cell subtype of pediatric diffuse large B-cell lymphoma in Japan: A retrospective cohort study.
    Hori D; Kobayashi R; Nakazawa A; Iwafuchi H; Klapper W; Osumi T; Ohk K; Sekimizu M
    Pediatr Blood Cancer; 2023 May; 70(5):e30279. PubMed ID: 36860130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
    Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
    Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
    Zheng W; Lin Q; Issah MA; Liao Z; Shen J
    BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Screening of Differential Expression Autophagy Genes Related to the Prognosis of Diffuse Large B-Cell Lymphoma and Establishment of an Autophagy Model].
    Zhang JD; Zhang HM; Lu D; Wang ZN; Chen HR; Lu XC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1101-1108. PubMed ID: 35981368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
    Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
    Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.
    Zhang Z; Zhao C; Yang S; Lu W; Shi J
    Lipids Health Dis; 2024 Jan; 23(1):20. PubMed ID: 38254162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
    Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
    Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.
    Ma S; Zhang B; Lu T; Li D; Li T; Shen Z; He C; Wang Y; Li B; Zhang H; Gu W; Wang C; Ye J; Zhu T; Miao Y; Wang L; Huang S; Liu Q; Sang W;
    Cancer; 2022 Oct; 128(19):3487-3494. PubMed ID: 35932292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
    Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
    Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes.
    Bao C; Gu J; Huang X; You L; Zhou Z; Jin J
    Cytokine; 2023 Sep; 169():156289. PubMed ID: 37453327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.